| UICC GLOBALink Presents... |
|
The Tobacco Reference Guide |
| by David Moyer, MD. |
| | Chapter 22 Smoking and tobacco cessation |
| | tobacco reference guideg (artefact pour |
| | Smoking and tobacco cessation: Nicotine replacement and |
| | pharmacologic treatment |
| | globalink (artefact pour saut de ligne) |
| | Nicotine patches were used by 5 million Americans and had $1 billion in sales in |
| | 1992, the year that they were first marketed. |
| | JAMA, May 26, 1993, p. 2615 |
| | tobacco reference guideg (artefact pour saut |
| | The 1997 market for smoking cessation products, after the nicotine patch was |
| | approved for over the counter sale, is expected to be $500 million to $1 billion, |
| | compared with about $250 million in 1996. |
| | Wall Street Journal, June 25, 1997, p. B1 |
| | tobacco reference guideg (artefact pour saut |
| | The 21- or 22-milligram nicotine patches release about the amount of nicotine that a |
| | smoker would get form 10 to 20 cigarettes a day, depending on the brand. |
| | 14-milligram patches are roughly equivalent to smoking 5 to 10 cigarettes a day. |
| | San Francisco Chronicle, April 1, 1992, p. D3 |
| | tobacco reference guideg (artefact pour saut |
| | Three-month nicotine patch therapy, even when used with virtually no behavioral |
| | treatment component, can produce one-year sustained abstinence rates of 11%. |
| | Though modest, this figure was a solid five-fold increase over placebo patches. |
| | Journal of Smoking-Related Disease 5:183, 1994 (supplement) |
| | tobacco reference guideg (artefact pour saut |
| | "Transdermal nicotine is safe and easy to use, has very good compliance, and |
| | increases quit rates by a factor of 2.5 even when smokers do not attend concurrent |
| | behavior therapy... At 3 months after their quit day, 29% of subject who ever used the |
| | patch reported not smoking currently... For these reasons, we believe state health |
| | departments, Medicaid, and Medicare programs, and health maintenance |
| | organizations should fully reimburse transdermal nicotine for poor smokers. It is ironic |
| | that in many states the poor can receive free treatment for non-life-threatening |
| | disorders such as otitis media, but can not receive free treatment for a dependence |
| | that has a 40% chance of causing their death." |
| | JAMA, July 19, 1995, p. 214 (John Hughes) |
| | tobacco reference guideg (artefact pour saut |
| | tobacco reference guideg (artefact pour |
| | Thursday, July 06, 2000 | Page 15 of 25 |
| | globalink (artefact pour saut de ligne) |
Last page of this chapter Copyright (©) 2000 - David Moyer - published on UICC GLOBALink |